Median RFS by subgroups
| Assessment and subgroups . | n . | Median RFS (mo) . | 95% CI . | Log rank P value . |
|---|---|---|---|---|
| WT1 decrease after first immunotherapy treatment in peripheral blood | ||||
| Yes | 11 | 37.0 | (7.0, 37.0) | .029 |
| No | 5 | 9.0 | (7.0, 13.0) | |
| WT1 decrease after first immunotherapy treatment in bone marrow | ||||
| Yes | 12 | NR | (NR, NR) | .744 |
| No | 8 | 37.0 | (9.0, NR) | |
| WT1 undetectable after transplant in peripheral blood | ||||
| Yes | 19 | NR | (37.0, NR) | .001 |
| No | 6 | 8.5 | (7.0, 13.0) | |
| WT1 undetectable at any time point post induction in peripheral blood | ||||
| Yes | 33 | 37.0 | (10.0, NR) | .018 |
| No | 8 | 7.0 | (2.0, 13.0) | |
| WT1 undetectable at any time point post induction in bone marrow | ||||
| Yes | 15 | NR | (11.0, NA) | .088 |
| No | 23 | 13.0 | (7.0, 37.0) | |
| WT1 undetectable at any time point post consolidation in peripheral blood | ||||
| Yes | 23 | 37.0 | (37.0, NR) | .004 |
| No | 6 | 8.5 | (7.0, 13.0) | |
| WT1 undetectable at any time point post consolidation in bone marrow | ||||
| Yes | 13 | NR | (NR, NR) | .049 |
| No | 16 | 28.0 | (9.0, 37.0) | |
| WT1 undetectable before ASCT in peripheral blood | ||||
| Yes | 19 | NR | (NR, NR) | .003 |
| No | 8 | 9.0 | (7.0, 37.0) | |
| Induced DTH response to autologous tumor | ||||
| Yes | 7 | NR | (NR, NR) | .029 |
| No | 19 | 28.0 | (9.0, NR) | |
| Induced antibody response to autologous tumor | ||||
| Yes | 5 | 37.0 | (8.0, NR) | .358 |
| No | 10 | NR | (NR, NR) | |
| Cytogenetic risk group (all patients who achieved CR) | ||||
| Good | 7 | NR | (6.0, NR) | <.001 |
| Normal/other | 33 | 37.0 | (9.0, NR) | |
| Poor | 6 | 4.0 | (1.0, 7.0) | |
| Cytogenetic risk group (all patients who received pre-ASCT immunotherapy treatment) | ||||
| Good | 4 | NR | (6.0, NR) | .001 |
| Normal/other | 22 | 37.0 | (28.0, NR) | |
| Poor | 2 | 6.5 | (6.0, 7.0) |
| Assessment and subgroups . | n . | Median RFS (mo) . | 95% CI . | Log rank P value . |
|---|---|---|---|---|
| WT1 decrease after first immunotherapy treatment in peripheral blood | ||||
| Yes | 11 | 37.0 | (7.0, 37.0) | .029 |
| No | 5 | 9.0 | (7.0, 13.0) | |
| WT1 decrease after first immunotherapy treatment in bone marrow | ||||
| Yes | 12 | NR | (NR, NR) | .744 |
| No | 8 | 37.0 | (9.0, NR) | |
| WT1 undetectable after transplant in peripheral blood | ||||
| Yes | 19 | NR | (37.0, NR) | .001 |
| No | 6 | 8.5 | (7.0, 13.0) | |
| WT1 undetectable at any time point post induction in peripheral blood | ||||
| Yes | 33 | 37.0 | (10.0, NR) | .018 |
| No | 8 | 7.0 | (2.0, 13.0) | |
| WT1 undetectable at any time point post induction in bone marrow | ||||
| Yes | 15 | NR | (11.0, NA) | .088 |
| No | 23 | 13.0 | (7.0, 37.0) | |
| WT1 undetectable at any time point post consolidation in peripheral blood | ||||
| Yes | 23 | 37.0 | (37.0, NR) | .004 |
| No | 6 | 8.5 | (7.0, 13.0) | |
| WT1 undetectable at any time point post consolidation in bone marrow | ||||
| Yes | 13 | NR | (NR, NR) | .049 |
| No | 16 | 28.0 | (9.0, 37.0) | |
| WT1 undetectable before ASCT in peripheral blood | ||||
| Yes | 19 | NR | (NR, NR) | .003 |
| No | 8 | 9.0 | (7.0, 37.0) | |
| Induced DTH response to autologous tumor | ||||
| Yes | 7 | NR | (NR, NR) | .029 |
| No | 19 | 28.0 | (9.0, NR) | |
| Induced antibody response to autologous tumor | ||||
| Yes | 5 | 37.0 | (8.0, NR) | .358 |
| No | 10 | NR | (NR, NR) | |
| Cytogenetic risk group (all patients who achieved CR) | ||||
| Good | 7 | NR | (6.0, NR) | <.001 |
| Normal/other | 33 | 37.0 | (9.0, NR) | |
| Poor | 6 | 4.0 | (1.0, 7.0) | |
| Cytogenetic risk group (all patients who received pre-ASCT immunotherapy treatment) | ||||
| Good | 4 | NR | (6.0, NR) | .001 |
| Normal/other | 22 | 37.0 | (28.0, NR) | |
| Poor | 2 | 6.5 | (6.0, 7.0) |
NR indicates not reached (a median RFS has not been reached).